Pfizer Inc., GlaxoSmithKline and NovaDigm Therapeutics ' Vaccine for Staph More Lethal Than Skin Cancer Tested

Published: Sep 17, 2012

A new wave of experimental vaccines is the medical community’s latest hope against a powerful staph infection that kills more people in the U.S. than skin cancer and costs as much as $8 billion a year to treat. Pfizer Inc. (PFE) and GlaxoSmithKline Plc (GSK), two of the world’s biggest drugmakers, and NovaDigm Therapeutics Inc., a closely held biotechnology company, are each testing novel vaccines to halt methicillin-resistant Staphylococcus aureus, or MRSA, long a dangerous infection in hospitals and nursing homes and which is now increasingly finding its way into daycare centers, schools and prisons.

Back to news